Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
Triparna Sen, B. Leticia Rodriguez, Limo Chen, et al.
Cancer Discovery (2019) Vol. 9, Iss. 5, pp. 646-661
Open Access | Times Cited: 705

Showing 1-25 of 705 citing articles:

Small-cell lung cancer
Charles M. Rudin, Élisabeth Brambilla, C. Faivre‐Finn, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 992
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Charles M. Rudin, John T. Poirier, Lauren A. Byers, et al.
Nature reviews. Cancer (2019) Vol. 19, Iss. 5, pp. 289-297
Open Access | Times Cited: 980
The Cytosolic DNA-Sensing cGAS–STING Pathway in Cancer
John Kwon, Samuel F. Bakhoum
Cancer Discovery (2019) Vol. 10, Iss. 1, pp. 26-39
Open Access | Times Cited: 861
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
Carl M. Gay, C. Allison Stewart, Elizabeth M. Park, et al.
Cancer Cell (2021) Vol. 39, Iss. 3, pp. 346-360.e7
Open Access | Times Cited: 673
Inflammatory microenvironment remodelling by tumour cells after radiotherapy
Martin McLaughlin, Emmanuel C. Patin, Malin Pedersen, et al.
Nature reviews. Cancer (2020) Vol. 20, Iss. 4, pp. 203-217
Closed Access | Times Cited: 609
The Next Decade of Immune Checkpoint Therapy
Padmanee Sharma, Bilal A. Siddiqui, Swetha Anandhan, et al.
Cancer Discovery (2021) Vol. 11, Iss. 4, pp. 838-857
Open Access | Times Cited: 539
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Constantia Pantelidou, Olmo Sonzogni, Mateus de Oliveira Taveira, et al.
Cancer Discovery (2019) Vol. 9, Iss. 6, pp. 722-737
Open Access | Times Cited: 532
Targeting DNA damage response pathways in cancer
Florian J. Groelly, Matthew Fawkes, Rebecca A. Dagg, et al.
Nature reviews. Cancer (2022) Vol. 23, Iss. 2, pp. 78-94
Closed Access | Times Cited: 433
Radiotherapy combined with immunotherapy: the dawn of cancer treatment
Zengfu Zhang, Xu Liu, Dawei Chen, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 351
STING: a master regulator in the cancer-immunity cycle
Yuanyuan Zhu, Xiang An, Xiao Zhang, et al.
Molecular Cancer (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 305
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Meng‐Ling Wu, Qianrui Huang, Yao Xie, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 293
The cGAS–STING pathway and cancer
Natasha Samson, Andrea Ablasser
Nature Cancer (2022) Vol. 3, Iss. 12, pp. 1452-1463
Closed Access | Times Cited: 291
Programmed death ligand 1 signals in cancer cells
Anand Kornepati, Ratna K. Vadlamudi, Tyler J. Curiel
Nature reviews. Cancer (2022) Vol. 22, Iss. 3, pp. 174-189
Open Access | Times Cited: 262
DNA Damage and Cancer Immunotherapy: A STING in the Tale
Timo Reisländer, Florian J. Groelly, Madalena Tarsounas
Molecular Cell (2020) Vol. 80, Iss. 1, pp. 21-28
Open Access | Times Cited: 243
Development of Immunotherapy Combination Strategies in Cancer
Timothy A. Yap, Eileen E. Parkes, Weiyi Peng, et al.
Cancer Discovery (2021) Vol. 11, Iss. 6, pp. 1368-1397
Open Access | Times Cited: 235
DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity
Changzheng Lu, Junhong Guan, Steve Lu, et al.
Cancer Cell (2020) Vol. 39, Iss. 1, pp. 96-108.e6
Open Access | Times Cited: 216
Research Advances in How the cGAS-STING Pathway Controls the Cellular Inflammatory Response
Dongshan Wan, Wei Jiang, Junwei Hao
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 211
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm
Yoshiaki Nakamura, Akihito Kawazoe, Florian Lordick, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 8, pp. 473-487
Closed Access | Times Cited: 211
Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy
Kyle M. Garland, Taylor L. Sheehy, John T. Wilson
Chemical Reviews (2022) Vol. 122, Iss. 6, pp. 5977-6039
Open Access | Times Cited: 207
Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy
Juyan Zheng, Junluan Mo, Tao Zhu, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 206
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
Anna F. Farago, Beow Y. Yeap, Marcello Stanzione, et al.
Cancer Discovery (2019) Vol. 9, Iss. 10, pp. 1372-1387
Open Access | Times Cited: 205
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
Michael J. Grant, Roy S. Herbst, Sarah B. Goldberg
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 10, pp. 625-644
Closed Access | Times Cited: 204
Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times
Christian Bailly, Xavier Thuru, Bruno Quesnel
NAR Cancer (2020) Vol. 2, Iss. 1
Open Access | Times Cited: 200
Targeting replication stress in cancer therapy
Alexandre André Balieiro Anastácio da Costa, Dipanjan Chowdhury, Geoffrey I. Shapiro, et al.
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 1, pp. 38-58
Closed Access | Times Cited: 187
cGAS-STING–mediated DNA sensing maintains CD8 + T cell stemness and promotes antitumor T cell therapy
Wenwen Li, Lu Lu, Juanjuan Lu, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 549
Closed Access | Times Cited: 185
Page 1 - Next Page

Scroll to top